Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease

I Gueorguieva, BA Willis, L Chua… - Clinical …, 2023 - Wiley Online Library
Donanemab is an amyloid‐targeting therapy that resulted in robust amyloid plaque
reduction and slowed Alzheimer's disease (AD) progression compared with placebo in the …
被引用次数：34 相关文章

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

I Gueorguieva, BA Willis, L Chua… - Clinical …, 2023 - pubmed.ncbi.nlm.nih.gov
Donanemab is an amyloid-targeting therapy that resulted in robust amyloid plaque reduction
and slowed Alzheimer's disease (AD) progression compared with placebo in the phase II …

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease.

I Gueorguieva, BA Willis, L Chua… - Clinical …, 2023 - search.ebscohost.com
Donanemab is an amyloid‐targeting therapy that resulted in robust amyloid plaque
reduction and slowed Alzheimer's disease (AD) progression compared with placebo in the …

Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease.

I Gueorguieva, BA Willis, L Chua, K Chow… - Clinical …, 2023 - europepmc.org
Donanemab is an amyloid-targeting therapy that resulted in robust amyloid plaque reduction
and slowed Alzheimer's disease (AD) progression compared to placebo in the phase 2 …